The randomized, double-blind, placebo-controlled TAP trial (n=868) found that early, empiric use of a clotting factor concentrate, 4F-PCC, in trauma patients requiring massive transfusion increased mortality and kidney injury compared to placebo. #massivehemorrhage #4F-PCC